Molecular Diagnostics News and Research

RSS

MiNDERA closes $1 million Seed financing round

MiNDERA Corp., a leader in non-invasive molecular diagnostics for dermatology and skin-related cancers, announced today the close of its $1 million Seed financing round. Scientific Health Development and other individual investors are among MiNDERA's new investors. This financing round will enable MINDERA to further validate its proprietary micro-needle technology and prepare for the launch of its first research products.

12 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Ambry Genetics presents groundbreaking TP53 gene data at ASHG; TP53 linked to breast cancer

Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.

9 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

New smartphone-based device can reliably perform molecular diagnoses at low cost

NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.

6 Oct 2015

New study finds that serum miRNA profiles change as myeloma progresses

Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.

30 Sep 2015

EKF’s new Altair 240 revealed to UK audience at IBMS 2015

EKF, announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham.

From EKF Diagnostics 24 Sep 2015

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company), today announced the availability of the U.S. Food and Drug Administration cleared BD MAX Enteric Parasite Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 24 Sep 2015

CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics DGX, +1.23% the world's leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD).

From Quest Diagnostics 18 Sep 2015

nCounterRNA:Protein pancancer immune profiling panel launched by NanoString

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of the nCounter® RNA:Protein PanCancer Immune Profiling Panel

From NanoString Technologies 11 Sep 2015

SKY92 genetic subtyping signature better than current markers in predicting progress of multiple myeloma

Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma patient.

9 Sep 2015

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

About 3% of colorectal cancers are due to Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers. Close blood relatives of patients with Lynch syndrome have a 50% chance of inheritance. The role that PMS2 genetic mutations play in Lynch syndrome has been underestimated in part due to technological limitations.

27 Aug 2015

Researchers design online database to help researchers identify cancer gene mutations

Many clinical trials use genome sequencing to learn which gene mutations are present in a patient's tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence.

27 Aug 2015

Next generation quantitative live-cell microscope released by Bruker

Bruker today announced the release of the Opterra II™ Multipoint Scanning Confocal Microscope, which represents the next generation of quantitative live-cell microscopes.

From Bruker 11 Aug 2015

Roche establishes strategic alliance with Diagnostic Laboratory Services

Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

From Roche Sequencing and Life Science 10 Aug 2015

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.

30 Jul 2015

Cepheid, FIND unveil new portable molecular diagnostics system for patients suspected of TB, HIV and Ebola

Cepheid and FIND today unveiled the GeneXpert Omni, the world's most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world.

28 Jul 2015

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

Viruses, not bacteria, are the most commonly detected respiratory pathogens in U.S. adults hospitalized with pneumonia, according to a New England Journal of Medicine study released today and conducted by researchers at Centers for Disease Control and Prevention and hospitals in Chicago and Nashville, including Vanderbilt University Medical Center.

15 Jul 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

From QIAGEN Manchester Limited 14 Jul 2015

Study aims to determine utility of Trovagene's PCM technology for predicting response to cancer immunotherapy

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.

8 Jul 2015